Abstract
Background: Evidence has suggested that aspirin reduces the incidence of several cancers, but these benefits may not occur with pancreatic cancer.
Methods: A 12-year nationwide longitudinal cohort merged with the health checkup data was divided into “exposure ascertainment period” and “outcome ascertainment period” to avoid immortal time bias. The daily defined dose system was used to indicate the drug exposure.
Results: We found no significant association between aspirin use and incident pancreatic cancer based on HR.
Conclusions: Aspirin does not prevent pancreatic cancer.
Impact: A large Asian cohort study with reliable medication information affirms no impact of aspirin on pancreatic cancer development.
- Received December 7, 2018.
- Revision received January 7, 2019.
- Accepted January 10, 2019.
- Published first January 14, 2019.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Volume 28, Issue 4
